European Journal of Internal Medicine
Volume 18, Issue 4 , Pages 309-313 , July 2007

Defining the metabolic syndrome: Resolving unresolved issues?

  • Jobien K. Olijhoek

      Affiliations

    • Internal Medicine, Section of Vascular Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands
    • Corresponding Author InformationCorresponding author. Internal Medicine, Section of Vascular Medicine, UMC Utrecht, F02.126, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Tel.: +31 30 250 9111; fax: +31 30 2518328.
    • ,
  • Yolanda van der Graaf

      Affiliations

    • Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands
    • ,
  • Steven M. Haffner

      Affiliations

    • Division of Clinical Epidemiology, University of Texas Health Sciences Centre, San Antonio, Texas, USA
    • ,
  • Frank L.J. Visseren

      Affiliations

    • Internal Medicine, Section of Vascular Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands
    • ,
  • for the SMART Study Group

      Affiliations

    • Members listed in the SMART Study Group.

Received 15 June 2006 ,Revised 11 October 2006 ,Accepted 12 October 2006.

References 

  1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486–2497
  2. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52:1210–1214
  3. Isomaa B, Almgren P, Tuomi T, Alexander CM, Landsman PB, Teutsch SM, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–689
  4. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–2716
  5. Olijhoek JK, van der Graaf Y, Banga JD, Algra A, Rabelink TJ, Visseren FL. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J. 2004;25:342–348
  6. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–359
  7. Gorter P, Olijhoek JK, Graaf van der Y, Algra A, Rabelink AJ, Visseren FLJ. Prevalence of the Metabolic Syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis. 2004;173:361–367
  8. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  9. Alberti KG, Zimmet P, Shwa J. The metabolic syndrome — a new worldwide definition. Lancet. 2005;366:1059–1062
  10. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752
  11. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  12. Sacks FM, Moye LA, Davis BR, Cole TG, Rouleau JC, Nash DT, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation. 1998;97:1446–1452
  13. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol. 1999;15:773–781
  14. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435
  15. Saely CH, Koch L, Schmid F, Marte T, Aczel S, Langer P, et al. Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. Diabetes Care. 2006;29:901–907
  16. Hanley AJ, Karter AJ, Williams K, Festa A, D'Agostino RB, Wagenknecht LE, et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation. 2005;112:3713–3721
  17. Katzmarzyk PT, Janssen I, Ross R, et al. The importance of waist circumference in the definition of metabolic syndrome: prospective analyses of mortality in men. Diabetes Care. 2006;29:404–409
  18. Lawlor DA, Smith GD, Ebrahim S. Does the new International Diabetes Federation definition of the metabolic syndrome predict CHD any more strongly than older definitions? Findings from the British Women's Heart and Health Study. Diabetologia. 2006;49:41–48

☆ Grant Support: The SMART study was financially supported by a grant of the University Medical Centre Utrecht.

PII: S0953-6205(07)00082-9

doi: 10.1016/j.ejim.2006.10.007

European Journal of Internal Medicine
Volume 18, Issue 4 , Pages 309-313 , July 2007

Article Tools